Medtronic Launches Study to Evaluate Implantable Device for Chronic Migraines

Strategic Insights -

The first patient implant for a study evaluating an implanted device to treat chronic migraines was conducted by Medtronic, Inc. in a 47-year-old female who has suffered from chronic headaches for eight years. The study, called Occipital Nerve Stimulation for the Treatment of Intractable Migraine (ONSTIM), involves a Medtronic Synergy neurostimulation device implanted near the occipital nerves at the base of the head. The neurostimulator delivers electrical impulses to determine patient response, which may lead to improved treatment options for those who have failed other treatments.

Key Takeaways:

  • Medtronic, Inc. announced the first patient implant in a preliminary study to evaluate the effectiveness of an implanted device for chronic migraines.
  • The study, called ONSTIM, involves a Medtronic Synergy neurostimulation device implanted in a 47-year-old female who has suffered from chronic headaches for eight years.
  • The neurostimulator delivers electrical impulses via insulated lead wires near the occipital nerves at the base of the head.
  • Study participants are adults who have had chronic migraines lasting at least 15 days per month over three months and have been refractory to other treatments.
  • The study aims to determine patient response to the implantable device, which may lead to improved treatment options for those who have failed other treatments.
  • The ONSTIM study involves seven medical centers in the U.S. and one medical center in Europe.
  • Medtronic received approval from the U.S. Food and Drug Administration to conduct the study.
  • The study aims to help the large numbers of people who have failed to respond to currently available treatments for chronic migraines.

Statistics:

  • 47-year-old female was the first patient to receive the implant.
  • Eight years is the length of chronic headache suffering of the study participant.
  • 7 medical centers in the U.S. and 1 medical center in Europe are participating in the ONSTIM study.
  • 15 days per month is the duration of chronic migraines required for study participation.
  • 3 months is the duration of chronic migraines required to be refractory to other treatments for study participation.

Sources:

  • NewsRx.com & NewsRx.net
  • Medtronic, Inc. (MDT)
  • Michigan Head Pain and Neurological Institute in Ann Arbor, Michigan.